louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06302712: Traditional Islamically Integrated Psychotherapy for Muslims With OCD in Pakistan
Official title: Cultural Adaptation and Evaluation of Traditional Islamically Integrated Psychotherapy for Muslim With OCD in Pakistan: A Mixed-Method Study.
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Obsessive-Compulsive Disorder
Lead sponsor: International Islamic University Malaysia
Sponsor class: OTHER
Collaborators: name: Foundation University Islamabad
First posted: 2024-03-12
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The current study aims to determine the effectiveness of the first culturally adapted Traditional Islamically Integrated Psychotherapy (TIIP) for Muslims with OCD in Pakistan along with the module effectiveness in reducing OCD symptoms with comorbidities like anxiety, depression, stress, thought control, thought-action fusion, and enhancing the spiritual quality of life of participants.


Eligibility criteria: Inclusion Criteria:

* The client diagnosed with OCD according to DSM-5-TR.
* The minimum score on Y-BOCS is 08 (i.e., indicating moderate level of symptoms)
* The age range is from 18 to 40 years
* The client has a minimum of eight years of formal education

Exclusion Criteria:

* The client is having a comorbid diagnosis of severe psychiatric illness (e.g., psychotic disorders, personality disorder, substance use disorder, neurocognitive disorder)
* The client is having a comorbidity of chronic physical illness
* The client refused to sign the informed consent form,
* The client has experience undergoing manualized faith-based CBT

Primary outcomes:
measure: Yale Brown Obsessive Compulsive Scale
timeFrame: 8 weeks
Secondary outcomes:
measure: Depression, Stress, Anxiety
timeFrame: 8 Weeks.
measure: Thought Action Fusion
timeFrame: 8 weeks
measure: Thought Control
timeFrame: 8 weeks
measure: Spiritual Quality
timeFrame: 8 weeks
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04368312: Psychological Impairment Due to Covid-19
Official title: Psychological Impairment Due to Covid-19 in Hospital Staff
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Psychological Distress
Quality of Life
Keywords: quality of life
psychological distress
Lead sponsor: University Hospital, Essen
Sponsor class: OTHER
First posted: 2020-04-29
Enrollment: 100
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Inclusion of all persons which can be attributed to hospital stuff, those include doctors and nurses (male/female)

Brief summary: Hospital staff and emergency personnel are expected to suffer impaired psychological outcomes during a pandemic in terms of Quality of Life, anxiety, depression or other outcomes. The Covid-19 pandemic is a threat for both somatic and psychological health, therefore the impact of the impairment of this event on psychological parameters has to be assessed.

Detailed description: Hospital staff and emergency personell are confronted with severe and life-threatening situations, therefore this group is considered to be at risk for impaired psychological health. A pandemic such as the Covid-19 endemic is suggested to severely impair the psychological state of this profession, amongst others Quality of life, anxiety, depression and other parameters. Therefore, it is crucial to assess the impact of impairment due to this global threat on the psychological health of health care providers. We therefore designed this study to evaluate baseline psychological characteristics and to re-assess those values in an interval of 60 days.

Eligibility criteria: Inclusion Criteria:

Hospital staff (doctors and nurses)

Exclusion Criteria:

None

Primary outcomes:
measure: PCL5 Questionnaire
timeFrame: 14 days
measure: BSI - Brief symptom inventory
timeFrame: 14 days
measure: PHQD
timeFrame: 14 days
measure: WHO - QoL BREF
timeFrame: 14 days
measure: STAXI
timeFrame: 14 days
measure: AUDIT questionnaire
timeFrame: 14 days
Secondary outcomes:
Other outcomes:
Locations:
city: Essen
country: Germany
facility: University Hospital Essen
state: NRW
Study officials:
References:
citation: Wesemann U, Hadjamu N, Wakili R, Willmund G, Vogel J, Rassaf T, Siebermair J. Gender Differences in Anger Among Hospital Medical Staff Exposed to Patients with COVID-19. Health Equity. 2021 Apr 19;5(1):181-184. doi: 10.1089/heq.2020.0119. eCollection 2021.
Clinical trial NCT05713812: "EFFECTS OF KINESIO-TAPING ON PAIN, POSTURAL STABILITY AND FUNCTION IN PERSONS WITH DISCOGENIC LOW BACK PAIN"
Official title: "EFFECTS OF KINESIO-TAPING ON PAIN, POSTURAL STABILITY AND FUNCTION IN PERSONS WITH DISCOGENIC LOW BACK PAIN"
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Low Back Pain
Low Back Pain, Mechanical
Lead sponsor: Foundation University Islamabad
Sponsor class: OTHER
First posted: 2023-02-06
Enrollment: 36
Sex: ALL
Minimum age (years): 20
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Low back pain is the leading cause of disability worldwide, the prevalence of low back pain can be as high as 43%. Past research has shown the positive effects of Kinesio taping in patients with chronic and nonspecific low back pain in pain reduction, improvement in postural stability, and improvement in function. However, no study has yet evaluated the effects of KT in persons with discogenic LBP. If found to be effective KT can be prescribed as a conservative \& cost-effective treatment for patients with discogenic low back pain.


Eligibility criteria: Inclusion Criteria:

* Age20-45 years.
* Positive straight leg raise (SLR)
* Posterolateral disc bulge, herniation or prolapse indicated by MRI.
* Positive centralization and peripheralization phenomenon.

Exclusion Criteria:

* Participants having spondylolisthesis, fractures, tumors, osteoporosis, infection, or spinal stenosis.
* History of lumbar spine surgery and patients that are already receiving any physical therapy or exercise
* Skin allergy or sensitivity to the tape.
* Neurological, rheumatologic, or psychiatric disease

Primary outcomes:
measure: Back Pain
timeFrame: 2 weeks.
measure: Postural Stability
timeFrame: 2 weeks.
measure: Disability
timeFrame: 2 weeks.
measure: Gait velocity
timeFrame: 2 weeks.
measure: Stride length
timeFrame: 2 weeks.
measure: Cadence
timeFrame: 2 weeks.
Secondary outcomes:
Other outcomes:
Locations:
city: Islamabad
country: Pakistan
facility: Foundation University Islamabad
state: Federal
Study officials:
affiliation: Foundation University Islamabad
name: Sameen Tariq, DPT
role: PRINCIPAL_INVESTIGATOR
affiliation: Foundation University Islamabad
name: Muhammad Osama, PhD*
role: STUDY_DIRECTOR
References:
Clinical trial NCT01156012: Efficacy and Safety Assessment of T2345 in Ocular Hypertensive or Glaucomatous Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Glaucoma
Lead sponsor: Laboratoires Thea
Sponsor class: INDUSTRY
First posted: 2010-07-02
Enrollment: 404
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to assess the efficacy and safety of T2345 versus active comparator.


Eligibility criteria: Inclusion Criteria:

* Adult patients diagnosed with glaucoma

Exclusion Criteria:

* Under 18.

Primary outcomes:
measure: Change From Baseline in Intraocular Pressure (IOP)
timeFrame: Day 0 and Day 84
Secondary outcomes:
Other outcomes:
Locations:
city: Clermont-Ferrand
country: France
facility: Medical Director
Study officials:
References:
Clinical trial NCT04611412: Determination of Risk Factors for the Development of Obesity and Hypertension in Children According to Perinatal Programming of Metabolism
Official title: Determination of Risk Factors for the Development of Obesity and Hypertension in Children According to Perinatal Programming of Metabolism
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Metabolic Syndrome
Keywords: Metabolic Syndrome
children
obesity
Lead sponsor: Samarkand State Medical Institute
Sponsor class: OTHER
First posted: 2020-11-02
Enrollment: 55
Sex: ALL
Minimum age (years): 12
Maximum age (years): 18
Standard ages: CHILD
ADULT
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: the cohort study will include 55 children aged 12 to 18 with exogenous constitutional obesity

Brief summary: to determine the risk factors for developing obesity in children with exogenous-constitutional obesity and arterial hypertension, according to the theories of early programming of metabolism

Detailed description: A retrospective cohort study of 55 children aged 12 to 18 years (average 14.60±0.24 years) with exogenous-constitutional obesity was conducted, with 24 girls (43.6%) and 31 (56.4%) boys. Children were identified during dispensary examinations in family clinics in Samarkand in the period 2018-2019. All the examined children belonged to the Uzbek population.

Eligibility criteria: Inclusion Criteria:

* SDS (standart deviation score) of body mass index (BMI) ranging from +2.0 to +3.0

Exclusion Criteria:

* secondary obesity and overweight genetic syndromes,
* refusal of the child and/or parents to be examined

Primary outcomes:
measure: Risk factors of metabolic syndrome
timeFrame: up to 36 months
Secondary outcomes:
Other outcomes:
Locations:
city: Samarkand
country: Uzbekistan
facility: Samarkand State Medical Institute
Study officials:
References:
Clinical trial NCT05722912: Expanded Access of Ruxolitinib Cream to Treat a Single Patient With cGVHD
Official title: Expanded Access of Ruxolitinib Cream to Treat a Single Patient With cGVHD
Study type: EXPANDED_ACCESS
Overall status: APPROVED_FOR_MARKETING
Conditions: Graft-versus-host Disease (GVHD)
Keywords: ruxolitinib
acute or chronic steroid-refractory GVHD
hematopoietic stem cell transplantation (allo-HSCT)
Lead sponsor: Incyte Corporation
Sponsor class: INDUSTRY
First posted: 2023-02-10
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT

Brief summary: To provide ruxolitinib through an expanded access to treat a single patient with cGVHD



Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Children's Hospital Medical Center, Cincinnati
name: Pooja Khandelwal, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT06235112: AI Detection of Incidental Coronary Artery Calcium to Enhance Cardiovascular Disease Prevention
Official title: AI Detection of Incidental Coronary Artery Calcium to Enhance Cardiovascular Disease Prevention: A Multicenter Randomized Trial
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Coronary Artery Disease
Lead sponsor: Brigham and Women's Hospital
Sponsor class: OTHER
Collaborators: name: Nano-X Imaging Limited
First posted: 2024-01-31
Enrollment: 1500
Sex: ALL
Minimum age (years): 40
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Randomized controlled trial of two arms, involving notification to providers (vs non-notification)
Primary purpose: PREVENTION

Brief summary: AI INFORM is a multicenter randomized trial that will test the hypothesis that providing clinicians information on the presence and amount of coronary artery calcifications (CAC), will result in initiation or intensification of preventive therapies. The study will use a cloud-based artificial intelligence (AI) platform (Nanox.AI) that can analyze non contrast chest CT and estimate the amount of CAC.


Eligibility criteria: Inclusion Criteria:

* Patients aged between 40-75 with prior chest CT within last 3 years

Exclusion Criteria:

* Prior coronary artery disease
* Prior cancer
* Other life-limiting condition

Primary outcomes:
measure: Proportion of participants with initiation or intensification of lipid-lowering therapy after intervention
timeFrame: 6 months
Secondary outcomes:
measure: Average change in LDL-C after intervention
timeFrame: 12 months
measure: Proportion of participants with downstream invasive or noninvasive testing after intervention
timeFrame: 12 months
measure: Proportion of participants with major adverse cardiovascular events after intervention
timeFrame: 12 months
measure: Proportion of participants with initiation or intensification of other preventive therapies after intervention
timeFrame: 6 months
Other outcomes:
Locations:
city: Boston
country: United States
facility: Brigham and Women's Hospital
state: Massachusetts
Study officials:
References:
Clinical trial NCT00383812: Intravitreal Bevacizumab for Polypoidal Choroidal Vasculopathy
Official title: Intravitreal Bevacizumab for Polypoidal Choroidal Vasculopathy
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Polypoidal Choroidal Vasculopathy
Keywords: Polypoidal choroidal vasculopathy
Intravitreal Bevacizumab
Lead sponsor: Asan Medical Center
Sponsor class: OTHER
First posted: 2006-10-04
Enrollment: 20
Sex: ALL
Minimum age (years): 20
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: 1. Primary objectives

   a. To evaluate the Effects of intravitreal Bevacizumab on polypoidal choroidal vasculopathy(PCV)
2. Secondary objectives

   1. To assess the changes in visual acuity
   2. To assess the change in lesion characteristics of PCV

      * size of PCV
      * fluorescein leakage
      * foveal thickness
   3. To investigate the safety of intravitreal Bevacizumab in patients with PCV
   4. To assess the effect of intravitreal Bevacizumab on the recurrence rate and the the incidence of submacular hemorrhage in patients with PCV


Eligibility criteria: Inclusion Criteria:

* Male or female, CNV secondary to PCV
* BCVA of 20/40 to 20/320 (Snellen equivalent)
* Evidence of presumed recent disease progression (blood, growth by FA, or recent VA loss)

Exclusion Criteria:

* Uncontrolled glaucoma or any other ocular condition that would prevent an improvement in visual acuity
* Media opacity in the study eye that precludes clinical and photographic evaluation
* Intraocular surgery \< 1 month before day 0
* Use of heparin/warfarin within 1 month prior to injection
* Known allergy or hypersensitivity to fluorescein, indocyanine green or povidone iodine
* Contraindication to pupil dilation in either eye
* Any condition which precludes patients' ability to comply with study requirements including completion of the study

Primary outcomes:
measure: To assess the percentage of patients who gained an improvement in best corrected visual acuity (BCVA) by 15 letters of more.
measure: To assess the percentage of patients whose final visual acuity resulted in Snellen equivalent of 20/200 or worse
Secondary outcomes:
measure: To investigate the resolution time of macular edema, subretinal fluid, and/or pigment epithelial detachment (PED) using optical coherence tomography (OCT)
measure: To evaluate change in size and leakage of PCV, using fluorescein angiography (FA) and/or indocyanine angiography (ICGA)
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Asan Medical Center
Study officials:
affiliation: Asan Medical Center
name: Young Hee Yoon, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Asan Medical Center
name: June-Gone Kim, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Asan Medical Center
name: Sun Young Lee, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Asan Medical Center
name: Hyewon Chung, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01847612: Use of Indocyanine Green Cholangiography and Methylene Blue to Detect Postoperative Biliary Fistula After Hepatectomy
Official title: Evaluation of Indocyanine Green Fluorescent Cholangiography Versus Methylene Blue to Detect Postoperative Biliary Fistula After Hepatectomy: Randomized Controlled Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Liver Disease
Keywords: per operative cholangiography
liver resection
biliary fistula
Lead sponsor: Centre Hospitalier Universitaire, Amiens
Sponsor class: OTHER
First posted: 2013-05-07
Enrollment: 132
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: The aim of the present study is to evaluate whether the use of indocyanine green fluorescent cholangiography is responsible in a decrease of biliary fistula's rate in patients with liver diseases requiring liver resection.


Eligibility criteria: Inclusion Criteria:

* benin or malignant liver disease with resection of 2 or more segments
* liver resection by laparotomy
* written consent

Exclusion Criteria:

* previous hepatectomy
* emergency surgery
* allergy to indocyanine green
* allergy to methylene blue
* pregnancy or breastfeeding

Primary outcomes:
measure: biliary fistula rate
timeFrame: postoperative week 4
Secondary outcomes:
Other outcomes:
Locations:
city: Amiens
country: France
facility: Amiens University Hospital
Study officials:
affiliation: CHU amiens
name: jean marc regimbeau, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Nguyen-Khac E, Lobry C, Chatelain D, Fuks D, Joly JP, Brevet M, Tramier B, Mouly C, Hautefeuille V, Chauffert B, Regimbeau JM. A Reappraisal of Chemotherapy-Induced Liver Injury in Colorectal Liver Metastases before the Era of Antiangiogenics. Int J Hepatol. 2013;2013:314868. doi: 10.1155/2013/314868. Epub 2013 Mar 7.
Clinical trial NCT03398512: HIPEC and Systemic Chemotherapy in Unresectable Peritoneal Metastases From Colorectal Cancer
Official title: A Study of Conversion Therapy Using Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) and Systemic Oxaliplatin/Capecitabine Chemotherapy in Unresectable Peritoneal Metastases From Colorectal Cancer
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Peritoneal Metastases From Colorectal Cancer
Lead sponsor: Wuhan University
Sponsor class: OTHER
First posted: 2018-01-12
Enrollment: 15
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The prognosis of patients with unresectable peritoneal metastases from colorectal cancer is poor. These patients may obtain survival benefit from radical colorectal resection and cytoreductive surgery (CRS). The response rates of previous conversion therapy are low. Hyperthermic intraperitoneal chemoperfusion (HIPEC) and systemic chemotherapy are effective methods of reducing peritoneal cancer index (PCI) levels. The purpose of this study is to investigate the efficacy and safety of HIPEC and systemic chemotherapy in the conversion therapy of peritoneal metastases from colorectal cancer.

Detailed description: To determine the efficacy and safety of HIPEC and systemic chemotherapy in the conversion therapy of peritoneal metastases from colorectal cancer, patients undergo HIPEC with Raltitrexed at the time of fist surgery and twice repeat within one week after the surgery, following 3 cycles of 3-week Oxaliplatin/Capecitabine chemotherapy. The second surgery, exploratory laparoscopy or laparotomy, is carried out one week later after the series of systemic chemotherapy.

Eligibility criteria: Inclusion Criteria:

* Histological proved diagnosis of colorectal cancer.
* Unresectable peritoneal metastases and primary tumor proved at surgery.
* No evidence of distant metastases.
* Have not received radiotherapy, chemotherapy or immunotherapy.
* ECOG score: 0\~2.
* Written informed consent is obtained prior to commencement of trial treatment.

Exclusion Criteria:

* Existence of distant metastasis outside the abdomen.
* Any previous radiotherapy, chemotherapy or immunotherapy.
* Active systemic infections.
* Inadequate cardiac function, renal function, liver function or bone marrow function at the beginning of the trial.
* Female patients who are pregnant or breast feeding

Primary outcomes:
measure: radical resection rate
timeFrame: 3 months
Secondary outcomes:
measure: the Peritoneal Cancer Index score
timeFrame: 3 months
measure: overall survival
timeFrame: 3 years
measure: complication rate
timeFrame: 3 years
Other outcomes:
Locations:
city: Wuhan
country: China
facility: Wuhan University
state: Hubei
Study officials:
References:
Clinical trial NCT02578212: Trust Game and Placebo Response
Official title: Trust Game and Placebo Response
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Placebo Effect
Pain
Trust
Lead sponsor: University Hospital, Basel, Switzerland
Sponsor class: OTHER
First posted: 2015-10-16
Enrollment: 106
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: In the proposed study, investigators aim to investigate the role of interpersonal trust in the conditioned placebo analgesia process with healthy male subjects in a standardized experimental heat pain paradigm.


Eligibility criteria: Inclusion Criteria:

* Men: age between 18 and 40 years old
* Healthy by self-report statement, thus no known current or chronic somatic diseases or psychiatric disorders
* Right-handedness (Oldfield, 1971)
* Willing to participate in study

Exclusion Criteria:

* Any acute or chronic disease (chronic pain, hypertension, heart disease, renal disease, liver disease, diabetes) as well as skin pathologies, neuropathies or nerve entrapment symptoms, sensory abnormalities affecting the tactile or thermal modality
* Current medications (psychoactive medication, narcotics, intake of analgesics) or being currently in psychological or psychiatric treatment
* Insufficient German language skills to understand the instructions
* Previous participation in studies using pain assessment (threshold and tolerance) with Peltier Devices
* Daily consumption of more than three alcoholic standard beverages per day (a standard alcoholic beverage is defined as either 3dl beer or 1 dl wine or 2cl spirits
* Current or regular drug consumption (THC, cocaine, heroin, etc.)

Primary outcomes:
measure: Visual analogue scale (VAS) rating (Intensity + unpleasantness of pain)
timeFrame: 2 hours
Secondary outcomes:
measure: Visual analogue scale (VAS) rating (trust)
timeFrame: 2 hours
measure: State-Trait-Anxiety (STAI- X1)
timeFrame: 2 hours
measure: State Trait Anger Expression (STAXI)
timeFrame: 2 hours
measure: Questionnaire about expectations (Erwartungsfragebogen)
timeFrame: 2 hours
measure: Questionnaire about the investigator (Fragebogen zum Versuchsleiter
timeFrame: 2 hours
measure: sociodemographic questionnaire (Soziodemographischer Fragebogen (SES))
timeFrame: 2 hours
measure: Questionnaire about Self-assessment of partnership binding (Bochumer Bindungsfragebogen - BoBi)
timeFrame: 2 hours
measure: State-Trait-Anxiety (STAI-X2 )
timeFrame: 2 hours
Other outcomes:
Locations:
city: Basel
country: Switzerland
facility: University of Basel
Study officials:
affiliation: Clinical Psychology and Psychotherapy, Department of Psychology, University of Basel
name: Jens Gaab, Prof
role: STUDY_CHAIR
References: